Sanofi builds case for Sarclisa, challenging J&J’s Darzalex

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma mark

ADC Therapeutics sets terms for $125m IPO

Swiss cancer drugs firm ADC Therapeutics has set the terms for a $125 million IPO to further develop its pipeline of antibody-drug conjugate drugs as they head towards regulatory review. 

FDA clears Lilly’s Retevmo for RET-positive lung, thyroid ca...

Eli Lilly now has a second approved drug from its takeover of Loxo Oncology last year after getting the go-ahead from the FDA for RET inhibitor Retevmo.

Menarini bags blood cancer drug with $677M Stemline acquisit...

J&J defends Darzalex with FDA approval for faster dosing

CHMP backs BMS’ first-in-class anaemia drug Reblozyl